Predictors and Intervention for Noncompliance
2 other identifiers
interventional
273
1 country
1
Brief Summary
This is a randomized controlled intervention trial in poorly compliant patients, testing whether improved compliance behavior decreases rates of acute rejection risk and graft loss. Hypothesis: A study of an intensive intervention focused on the least compliant patients and beginning 3 months post-transplant. Effective intervention will reduce the number of acute rejection episodes and thus the occurrence of chronic rejection and graft loss.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Aug 1998
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 1998
CompletedFirst Submitted
Initial submission to the registry
September 2, 2005
CompletedFirst Posted
Study publicly available on registry
September 7, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2014
CompletedJune 1, 2015
May 1, 2015
16.3 years
September 2, 2005
May 28, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Graft loss
prospective
Secondary Outcomes (2)
Acute rejection
prospective
Death
prospective
Study Arms (1)
Phone calling
EXPERIMENTALPhone calling to encourage improved adherence
Interventions
Eligibility Criteria
You may qualify if:
- Kidney transplant
- Discharged from hospital with functioning graft
You may not qualify if:
- Risk of recurrent primary renal disease, e.g. hemolytic uremic syndrome, oxalosis, membranoproliferative glomerulonephritis type II, focal,segmental glomerulosclerosis with nephrotic syndrome
- Patients with active psychosis
- Patients not using azathioprine, sirolimus, or mycophenolate mofetil for immunosuppression at the time of discharge
- Patients taking the liquid form of azathioprine or mycophenolate mofetil
- Patients who are younger than 14 yrs. old
- Patients who do not speak English
- Receiving extra-renal organ except for pancreas,either simultaneously or previously
- Patients who live and will be followed outside of the United States, except Canada
- Patients who are physically unable to open the Medication Event Monitoring System(MEMS)cap
- Patients who are not responsible for taking their own medications, e.g. living in a medical care facility
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Minnesota
Minneapolis, Minnesota, 55455, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Thomas E Nevins, MD
University of Minnesota
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 2, 2005
First Posted
September 7, 2005
Study Start
August 1, 1998
Primary Completion
November 1, 2014
Study Completion
December 1, 2014
Last Updated
June 1, 2015
Record last verified: 2015-05